AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19935992
Drug: Fluoroscopically directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopically directed caudal epidural steroid injections with local anesthetic, steroids, and 0.9% sodium chloride solution.
Trial: 19935992
Drug: Fluoroscopically directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopically directed caudal epidural steroid injections
Trial: 15259905
Drug: Once-daily saquinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily saquinavir/ritonavir 1600/100 mg
Trial: 15259905
Drug: Once-daily saquinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily saquinavir/ritonavir 2000/100 mg
Trial: 15259905
Drug: Twice-daily saquinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily saquinavir/ritonavir 1000/100 mg
Trial: 2060551
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (BUD) 0.8, 1.6, and 3.2 mg/day
Trial: 2060551
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (PRED) 5, 10, and 20 mg/day
Trial: 25467598
Drug: Combined Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Breast Feeding and Music Therapy (BF+MT)
Trial: 23837690
Drug: Go-rei-San (GRS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Go-rei-San (GRS) 7.5 g orally the day before surgery
Trial: 21845249
Drug: Lateral Ridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral Ridge Augmentation (LRA)
Trial: 18059031
Drug: alpha tocopherol
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha tocopherol (400 IU/day) and beta carotene (30 mg/day) supplements
Trial: 15232810
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium chloride (MgCl2), 50 mmol/24 hours, administered for 36 hours after induction of anesthesia
Trial: 1370509
Drug: Opiate exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate exposure (dihydrocodeine, hydrocodone, codeine, morphine)
Trial: 6372855
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir for 7 days
Trial: 3015401
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (lomustine, cyclophosphamide, vincristine, cisplatin, and doxorubicin monthly)
Trial: 3015401
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (five-drug regimen on Months 1, 3, and 5; 5-FU by constant infusion, methotrexate, and mitomycin on Months 2, 4, and 6)
Trial: 18248490
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg q.d.)
Trial: 15916709
Drug: Irvingia gabonensis
RxNorm normalized name: IRVINGIA GABONENSIS SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irvingia gabonensis (IG) 1.05 g three times a day for one month
Trial: 6682617
Drug: Hydralazine (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (225 mg/day)
Trial: 6682617
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (160 mg/day)
Trial: 6682617
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Hydralazine and Isosorbide dinitrate (H + I)
Trial: 28885231
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment in NP(+) group
Trial: 28885231
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment in NP(-) group
Trial: 11585015
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy targeting diastolic dysfunction
Trial: 9143253
Drug: Live oral
RxNorm normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live oral polio virus vaccine
Trial: 7496197
Drug: Pentamidine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine therapy at the beginning of the nervous stage
Trial: 7496197
Drug: Arsobal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arsobal therapy (2, 16 mg/kg/d for 10 consecutive days)
Trial: 26018967
Drug: DFMO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO therapy
Trial: 2897207
Drug: Beta-mimetic tocolytic
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-mimetic tocolytic administration
Trial: 28701336
Drug: Reframe-IT plus
RxNorm normalized name: Sooth-It Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reframe-IT plus treatment as usual (TAU)
Trial: 23835112
Drug: Hydrochlorothiazide and
RxNorm normalized name: hydrochlorothiazide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide and Losartan (L/H)
Trial: 17343938
Drug: Split course
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split course bifractionated radiotherapy at 1.6 Gy/fraction, twice daily, 5 days/week to 70.4 Gy/6 weeks
Trial: 11913269
Drug: Vitamin tablet
RxNorm normalized name: Hexavitamin Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin tablet containing seven active ingredients
Trial: 23629985
Drug: Analgesics (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics (control group, n=26)
Trial: 15016635
Drug: Pharmacologically induced
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologically induced preconditioning (PI-SWOP) with 10 mg nitroglycerin
Trial: 2650695
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid supplement (10 g of fish oil containing 3 g n-3 fatty acids, 1.8 g eicosapentaenoic acid)
Trial: 2650695
Drug: Placebo (isoenergetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isoenergetic supplement containing olive oil)
Trial: 24210590
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (ARBs) losartan
Trial: 24210590
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (ARBs) irbesartan
Trial: 17694461
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (100 microg/min for 12 hours after PCI)
Trial: 15662235
Drug: Continue antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue antihypertensive therapy
Trial: 15662235
Drug: Stop antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop antihypertensive therapy
Trial: 11985763
Drug: Salbutamol, 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol, 0.8 mg four times daily for 2 weeks
Trial: 9496408
Drug: Fosfomycin tromethamine
RxNorm normalized name: FOSFOMYCIN TROMETHAMINE
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin tromethamine 3.0 g (single dose)
Trial: 9496408
Drug: Standard agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard agents (nitrofurantoin, norfloxacin, trimethoprim/sulfamethoxazole)
Trial: 6299050
Drug: Cyclofenil, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclofenil, 400 mg/day
Trial: 6299050
Drug: Conjugated estrogens,
RxNorm normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens, 1.25 mg/day
Trial: 27959333
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high dose of dexamethasone
Trial: 17589976
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 to 3 mg kg(‐1) hour(‐1))
Trial: 9753251
Drug: Rebamipide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (300 mg three times a day) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Trial: 9753251
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rebamipide) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Trial: 29474685
Drug: HealtheSteps™ lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HealtheSteps™ lifestyle prescription program (in-person coaching sessions, goal setting and tracking, technology supports)
Trial: 29474685
Drug: HealtheSteps™ lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HealtheSteps™ lifestyle prescription program
Trial: 21205592
Drug: PCI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI with drug eluting stents
Trial: 18285440
Drug: Randomized treatments
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatments
Trial: 10699160
Drug: Daclizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1.0 mg per kilogram of body weight), given intravenously within 24 hours after surgery and every two weeks thereafter for a total of five doses
Trial: 10699160
Drug: Generalized immunosuppressive
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalized immunosuppressive therapy (control group)
Trial: 9124468
Drug: Melatonin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (1 mg 30 min before and 0.75 mg 120 min after light exposure)
Trial: 8166887
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg (n = 61)
Trial: 25211359
Drug: Riboflavin solution
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin solution with 20% dextran
Trial: 25211359
Drug: Dextran-free riboflavin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran-free riboflavin solution
Trial: 22687313
Drug: Control (antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antibiotic therapy only)
Trial: 16243989
Drug: ODT ondansetron
RxNorm normalized name: Ondansetron Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODT ondansetron 8 mg
Trial: 10665675
Drug: Robot-aided therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-aided therapy during acute rehabilitation
Trial: 10665675
Drug: Standard acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard acute rehabilitation treatment
Trial: 2533023
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg/die for 14 days)
Trial: 2533023
Drug: Piroxicam beta-cyclodextrin
RxNorm normalized name: piroxicam-beta-cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam beta-cyclodextrin (20 mg/die for 14 days)
Trial: 24294744
Drug: Local probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local probiotics vaginal medicine (10 applications) containing Lactobacillus acidophilus and Lactobacillus rhamnosus
Trial: 24294744
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day)
Trial: 24294744
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day) + local probiotics (starting day 5)
Trial: 21569374
Drug: Temporary ovarian
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary ovarian suspension (elevating both ovaries to the anterior abdominal wall using a Prolene suture) post-operatively
Trial: 11134099
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel 100 mg/day
Trial: 11134099
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel 50 mg to 75 mg/day
Trial: 11134099
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel 100 mg to 75 mg/day
Trial: 11134099
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (both doses)
Trial: 26928845
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel
Trial: 11134099
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone patch (2 patches delivering 5 mg T/day)
Trial: 9307537
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of prostaglandin E2 (2 mg)
Trial: 8349432
Drug: Oral menogaril
RxNorm normalized name: ceftobiprole medocaril sodium Injection [Zevtera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral menogaril (85 mg/m2 to 625 mg/m2 every 4 weeks)
Trial: 8349432
Drug: Alternating oral
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating oral and IV menogaril (250 mg/m2 IV; 250-500 mg/m2 oral)
Trial: 8349432
Drug: Oral menogaril
RxNorm normalized name: ceftobiprole medocaril sodium Injection [Zevtera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral menogaril
Trial: 19068454
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day, 4 weeks 'on' and 2 weeks 'off')
Trial: 10937788
Drug: Computer-administered SCL-90-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-administered SCL-90-R
Trial: 8146033
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg maprotiline
Trial: 8146033
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg aminophylline
Trial: 2873974
Drug: Lidamidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidamidine (10 mg per os)
Trial: 21332653
Drug: 100‐min infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100‐min infusion of gemcitabine
Trial: 21332653
Drug: 30‐min infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐min infusion of gemcitabine
Trial: 21332653
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion after week 1
Trial: 15060511
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg orally once daily for 4 days
Trial: 11755894
Drug: ADL 8‐2698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADL 8‐2698 (6.0 mg)
Trial: 11755894
Drug: ADL 8‐2698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADL 8‐2698 (0.5 to 3.0 mg)
Trial: 11755894
Drug: ADL 8‐2698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADL 8‐2698 (> or = 3.0 mg)
Trial: 11755894
Drug: ADL 8‐2698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADL 8‐2698 (lower doses)
Trial: 7867676
Drug: Valsartan 40
RxNorm normalized name: valsartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 40 mg
Trial: 2840815
Drug: Lisinopril 2.5
RxNorm normalized name: lisinopril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 2.5 mg
Trial: 3617239
Drug: Combined intramuscular
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intramuscular and oral estrogen treatment (ESTR, n = 39)
Trial: 22211444
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy intervention to decrease HIV-related risk behavior and trauma-related stress symptoms
Trial: 15987864
Drug: Multivitamin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplementation (20 mg thiamine, 20 mg riboflavin, 25 mg B-6, 50 microg B-12, 500 mg C, 30 mg E, and 0.8 mg folic acid)
Trial: 15987864
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (30 mg beta-carotene plus 5000 IU preformed vitamin A)
Trial: 10702649
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine
Trial: 27899067
Drug: Conventionally estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally estimated drug effect
Trial: 25298576
Drug: Conventional interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional interferon (INF) α2a, 3MIU, S.C and ribavirin 1000 mg PO for 24 weeks in genotype 3 and 48 weeks in genotype 1 and 4 HCV patients.
Trial: 22670901
Drug: Delamanid 100
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Delamanid 100 mg twice daily
Trial: 22670901
Drug: Delamanid 200
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Delamanid 200 mg twice daily
Trial: 17885344
Drug: Heatwrap therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heatwrap therapy in addition to oral analgesics
Trial: 26058405
Drug: Oral analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics (control group)
Trial: 12183263
Drug: Gentamicin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin concentration at surgical closure < 0.5 mg/liter
Trial: 12183263
Drug: Gentamicin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin concentration at surgical closure ≥ 1.6 mg/liter
Trial: 10728175
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for bulimia nervosa
Trial: 9815934
Drug: Cisplatin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, 80 mg/m2, three times every 3 weeks
Trial: 9815934
Drug: Carboplatin, 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin, 375 mg/m2, three times every 3 weeks
Trial: 1952429
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate (0.025 mg/kg body weight)
Trial: 7281826
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PETN
Trial: 7281826
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg PETN
Trial: 30765429
Drug: Proximal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Trial: 30765429
Drug: Distal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Trial: 30765429
Drug: Intravenous isoglycemic
RxNorm normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isoglycemic clamp studies
Trial: 28993935
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (n=39)
Trial: 28993935
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (n=18)
Trial: 15941455
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment programme (n = 21)
Trial: 6600426
Drug: Aspirin (2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2.6 g/day)
Trial: 30578873
Drug: Risankizumab (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (90 mg)
Trial: 30578873
Drug: Risankizumab (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (180 mg)
Trial: 19776683
Drug: High group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High group (target serum glucose concentration 9‐11 mmol/l)
Trial: 19776683
Drug: Low group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low group (target serum glucose concentration 5‐7 mmol/l)
Trial: 17276272
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with intracameral nonpreserved lidocaine 0.5% (Group 2)